Declaration of Confidentiality Sample Clauses

A Declaration of Confidentiality is a clause that obligates parties to keep certain information private and not disclose it to unauthorized individuals or entities. Typically, it applies to sensitive business data, trade secrets, or proprietary information shared during the course of a relationship, such as during negotiations or while performing contractual duties. This clause serves to protect valuable or sensitive information from being leaked or misused, thereby safeguarding the interests and competitive advantage of the disclosing party.
POPULAR SAMPLE Copied 58 times
Declaration of Confidentiality. I have read and understand the foregoing confidentiality policy and procedures of NeighborImpact and understand that violation of this policy may result in termination of employment or volunteer services, or in the case of independent contractors, contract termination.
View SourceView Similar (4)
Declaration of Confidentiality. 22.1 By signing this Framework Agreement, the Contractor confirms that it is aware of the contents of the Declaration of Confidentiality as attached hereto as Schedule 2 and that it will arrange for any subcontractor, persons or auxiliary persons (including employees) that it engages for the Services to sign this declaration and send it to FMO. 22.2 The confidentiality obligations as described in Declaration of Confidentiality shall not apply if FMO has given Contractor prior written consent to disclose particular information.
View SourceView Similar (2)
Declaration of Confidentiality. As a condition of obtaining access to information concerning procedures or other data records utilized/ maintained by the Department of Health Care Services (“DHCS”) and ▇▇▇▇▇▇▇. COUNTY MEDI-CAL MANAGED CARE COMMISSION, a public entity doing business as Gold Coast Health Plan, I, __________________ agree not to divulge any information obtained in the course of my assignment to unauthorized persons, and I agree not to publish or otherwise make public any information regarding persons receiving Medi-Cal services such that the persons who receive such services are identifiable. Access to such data shall be limited to Gold Coast Health Plan authorized employees who require the information in the performance of their duties, State and federal personnel who require the information in the performance of their duties, and to such others as may be authorized by Gold Coast Health Plan. I acknowledge that I have received a copy of Exhibit G of Client’s contract with DHCS, and I agree to the restrictions and conditions therein. I recognize that unauthorized release of confidential information may subject me to civil and criminal sanctions pursuant to the provisions of the Welfare and Institutions Code Section 14100.2. Name of Subcontractor ________________________ The undersigned hereby certifies that the following information regarding (the “Organization”) is true and correct as of the date set forth below. 1. Officers/Directors General Partners: 2. Co-Owners: 3. Stockholders owning more than ten percent (10%) of the stock of the Organization: 4. Major creditors holding more than five percent (5%) of Organization’s debt: 5. Form of Organization (Corporation, Partnership, Sole Proprietorship, Individual): 6. If not already disclosed above, is Organization, either directly or indirectly, related to or affiliated with the Health Plan? Explain: By: Print Name: Dated: Title
View Source
Declaration of Confidentiality. In consideration of us agreeing to make available to you certain information by your signature of a copy of this letter you agree as follows:
View SourceView Similar (2)
Declaration of Confidentiality. If County has access to computer files or any data confidential by statute, including identification of eligible Members, County agrees to sign a declaration of confidentiality in accordance with the applicable Government Contract and in a form acceptable to CalOptima and DHCS, DMHC MRMIB and/or CMS, as applicable.
View SourceView Similar (11)
Declaration of Confidentiality. All the information you receive in conjunction with XXX evaluation process is strictly confidential.
View Source
Declaration of Confidentiality. I confirm that I have read, understood and accepted the code of conduct for experts established in Annex 2 to the contract sent by EFSA.
View SourceView Similar (2)
Declaration of Confidentiality. ‌ It is confirmed that during participation in the tender competition and signing of the contract, the duty of confidentiality in accordance with section 27 of The Act relating to Innovation Norway and section 121 of the Norwegian Penal Code shall be complied with.
View Source
Declaration of Confidentiality. It is confirmed that during participation in the tender competition and signing of the contract, the duty of confidentiality in accordance with section 27 of The Act relating to Innovation Norway and section 121 of the Norwegian Penal Code shall be complied with. This applies, among other things, to the following: Services or work performed for Innovation Norway require a sense of responsibility and loyalty The provisions set forth in section 27 of the Act relating to Innovation Norway stipulate a duty of confidentiality with regard to what one becomes aware of, in connection with service or work, concerning others’ business-related or private affairs All information shall be treated in a satisfactory and, for unauthorised parties, inaccessible manner and otherwise in accordance with Innovation Norway's guidelines currently in force The duty of confidentiality also applies to employees of Innovation Norway who do not have a need to know the information for their work The duty of confidentiality also applies after the end of my service or work for Innovation Norway Breach of the duty of confidentiality may entail criminal liability, liability for damages and/or termination of my service or work for Innovation Norway.
View Source

Related to Declaration of Confidentiality

  • Obligation of Confidentiality 14.1 During the Term, and for [***] thereafter, each of the Parties will keep confidential and not disclose or use any of the Information of the other Party except in the performance of its obligations and exercise of its rights under this Agreement. Each Party will treat the other Party’s Information with the same degree of confidentiality as it keeps its own confidential information (but in no event will it use less than reasonable care with such Information). Notwithstanding the foregoing, the provisions of this Article 14 shall not apply to any information that can be shown by the Receiving Party: (a) To have been known to or in the possession of the Receiving Party prior to the date of its actual receipt from the Disclosing Party without breaching any provision of this Agreement or any other agreement between the Parties or of any agreement between the Disclosing Party and a Third Party, by such Third Party; (b) To be or to have become available to the public other than through any act or omission of the Receiving Party in breach of this Agreement or any other agreement between the Parties; (c) To have been disclosed to the Receiving Party, other than under an obligation of confidentiality, by a Third Party that had no obligation to the Disclosing Party not to disclose such information to others; or (d) To have been subsequently independently developed by the Receiving Party without use of the Disclosing Party Information as demonstrated by competent contemporaneous tangible records. 14.2 Receiving Party shall ensure that its Affiliates, directors or employees, who have access to Information, shall consider and hold any of the Information as herein contemplated. 14.3 Each Party may disclose the other Party’s Information hereunder solely to the extent such disclosure is reasonably necessary in connection with complying with applicable laws; provided that in the event of any such disclosure of the Disclosing Party’s Information by the Receiving Party, the Receiving Party will, except where impracticable, give reasonable advance notice to the Disclosing Party of such disclosure requirement (so that the Disclosing Party may seek a protective order and/or other appropriate remedy or waive compliance with the confidentiality provisions of this Article 14 and will use its Commercially Reasonable Efforts to secure confidential treatment of such confidential Information required to be disclosed). 14.4 Each Receiving Party shall keep Information belonging to the Disclosing Party in appropriately secure locations. Upon expiration or termination of this Agreement, any and all Information possessed in tangible form by a Receiving Party, or its Affiliates, or its or any of their directors, officers, employees, agents, consultants, and clinical investigators and belonging to the Disclosing Party, shall, upon written request, be destroyed to the extent practicable and not used or disclosed by the Receiving Party, its Affiliates, or any of their directors, officers, employees, agents, consultants, and clinical investigators; provided, however, that a Party may retain one (1) copy of any Information in an appropriately secure location solely for use by its legal department to ensure compliance with the confidentiality provisions of this Agreement. 14.5 DAEWOONG and AEON each acknowledge the other Party’s interest in publishing the results of its scientific research in order to obtain recognition within the scientific community and to advance the state of scientific knowledge. Authorship of any publication shall be determined based on the accepted standards used in peer-reviewed, academic journals at the time of the proposed publication. Each Party also recognizes the mutual interest in obtaining valid patent protection and in protecting business interests and trade secret information. Consequently, except for disclosures permitted pursuant to Article 14.1, if either Party, its employees or consultants wishes to publish or present to any third party, during the Term, results of the scientific, preclinical and clinical studies or any information about Product, or the results of any program to discover or develop any of the above, it shall deliver to the other Party a copy of the proposed written publication or an outline of an oral disclosure at least fifteen (15) days prior to submission for publication or presentation. The reviewing Party shall notify the other Party within fifteen (15) days of receipt of such proposed publication whether such draft publication contains (i) Information of the reviewing Party, or (ii) information that if published would have an adverse effect on a patent application covering the subject matter of this Agreement, the reviewing Party shall have the right to (a) propose modifications to the publication or presentation for patent reasons, trade secret reasons, confidentiality reasons or business reasons or (b) request a reasonable delay in publication or presentation in order to protect patentable information. If the reviewing Party requests a delay to protect patentable information, the publishing Party shall delay submission or presentation for a period not to exceed thirty (30) days to enable patent applications protecting each Party’s rights in such information to be filed in accordance with the terms of this Agreement. Upon expiration of such thirty (30) days, the publishing Party shall be free to proceed with the publication or presentation. If the reviewing Party reasonably requests modifications to the publication or presentation to prevent disclosure of material trade secret or proprietary business information, the publishing Party shall edit such publication to prevent the disclosure of such information prior to submission of the publication or presentation. After the termination or expiration of this Agreement, the Parties shall continue to be obligated to adhere to the guidelines set out in Article 14.4 and this Article 14.5, but solely with respect to publications or presentations to any third party containing information about Product. 14.6 Once approval for a publication or presentation has been granted, the relevant Party shall be entitled to use the specific information contained in such publication or presentation after the date of its publication or presentation without seeking further approval. General comments made by a Party relating to the relationship between DAEWOONG and AEON established by this Agreement, including, for example, general comments made in response to inquiries at professional meetings and other similar circumstances, are not intended to be restricted by the provisions of this Article 14 provided such information has been disclosed to the public previously or cleared for such disclosure by the other Party. For the avoidance of doubt, neither Party shall be entitled to publish Information of the other in violation of Article 14. 14.7 DAEWOONG and AEON shall agree upon the timing and content of an initial press release relating to this Agreement and the transactions contemplated herein. Except to the extent already disclosed in that initial press release, no disclosure of the subject matter of this Agreement or its terms may be made by either Party, and no Party shall use the name, trademark, trade name or logo of the other Party or its employees in any publicity, news release or disclosure relating to this Agreement or its subject matter, without the prior express written permission of the other Party, except as may be required by applicable laws, regulations, or judicial order. The Party desiring to make any such public announcement shall provide the other Party with a written copy of the proposed announcement in sufficient time prior to public release to allow such other Party to comment upon such announcement, prior to public release.

  • Certificate of Confidentiality Effective June 11, 2017 the Certificate of Confidentiality (Certificate) issued for the database of Genotypes and Phenotypes (dbGaP) is subject to the requirements of section 301(d) of the Public Health Service Act (42 U.S.C. 241(d)). Moreover, as of October 1, 2017 dbGaP is required to adhere to the NIH Policy for Issuing Certificates of Confidentiality (NOT-OD-17-109). Therefore, Approved Users of dbGaP, whether or not funded by the NIH, who access a copy of information protected by a Certificate held by dbGaP, are also subject to the requirements of the Certificate of Confidentiality and subsection 301(d) of the Public Health Service Act. Under Section 301(d) of the Public Health Service Act and the NIH Policy for Issuing Certificates of Confidentiality, recipients of a Certificate of Confidentiality shall not: • Disclose or provide, in any Federal, State, or local civil, criminal, administrative, legislative, or other proceeding, the name of such individual or any such information, document, or biospecimen that contains identifiable, sensitive information about the individual and that was created or compiled for purposes of the research, unless such disclosure or use is made with the consent of the individual whom the information, document, or biospecimen pertains; or • Disclose or provide to any other person not connected with the research the name of such an individual or any information, document, or biospecimen that contains identifiable, sensitive information about such an individual and that was created or compiled for purposes of the research. Disclosure is permitted only when: • Required by Federal, State, or local laws (e.g., as required by the Federal Food, Drug, and Cosmetic Act, or state laws requiring the reporting of communicable diseases to State and local health departments), excluding instances of disclosure in any Federal, State, or local civil, criminal, administrative, legislative, or other proceeding; • Necessary for the medical treatment of the individual to whom the information, document, or biospecimen pertains and made with the consent of such individual; • Made with the consent of the individual to whom the information, document, or biospecimen pertains; or • Made for the purposes of other scientific research that is in compliance with applicable Federal regulations governing the protection of human subjects in research.